Financhill
Sell
33

PTN Quote, Financials, Valuation and Earnings

Last price:
$1.00
Seasonality move :
-3.65%
Day range:
$0.90 - $1.05
52-week range:
$0.68 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
19.11x
Volume:
397.6K
Avg. volume:
1.1M
1-year change:
-76.7%
Market cap:
$23.2M
Revenue:
$4.5M
EPS (TTM):
-$1.97

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PTN
Palatin Technologies
-- -$0.42 -100% -25% $17.00
IBIO
iBio
-- -$0.46 -100% -62.35% $4.78
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 -60.77% -99.16% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PTN
Palatin Technologies
$0.99 $17.00 $23.2M -- $0.00 0% --
IBIO
iBio
$3.17 $4.78 $31.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.2M -- $0.00 0% 0.07x
NNVC
Nanoviricides
$1.33 -- $19.1M -- $0.00 0% --
OGEN
Oragenics
$0.27 -- $3.3M -- $0.00 0% 1.05x
TOVX
Theriva Biologics
$1.43 -- $4M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PTN
Palatin Technologies
-- -3.039 -- 0.99x
IBIO
iBio
5.96% 8.122 3.92% 1.49x
NBY
NovaBay Pharmaceuticals
4.54% 0.531 1.51% 0.75x
NNVC
Nanoviricides
-- 2.048 -- --
OGEN
Oragenics
-- 2.260 -- --
TOVX
Theriva Biologics
-- -1.924 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M
IBIO
iBio
-- -$4.4M -83.08% -110.9% -2153.5% -$3.9M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$3.2M -- -- -- -$2.6M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M

Palatin Technologies vs. Competitors

  • Which has Higher Returns PTN or IBIO?

    iBio has a net margin of -2357.27% compared to Palatin Technologies's net margin of -2182%. Palatin Technologies's return on equity of -- beat iBio's return on equity of -110.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
    IBIO
    iBio
    -- -$0.48 $14.8M
  • What do Analysts Say About PTN or IBIO?

    Palatin Technologies has a consensus price target of $17.00, signalling upside risk potential of 1617%. On the other hand iBio has an analysts' consensus of $4.78 which suggests that it could grow by 50.79%. Given that Palatin Technologies has higher upside potential than iBio, analysts believe Palatin Technologies is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PTN
    Palatin Technologies
    0 0 0
    IBIO
    iBio
    2 0 0
  • Is PTN or IBIO More Risky?

    Palatin Technologies has a beta of 0.873, which suggesting that the stock is 12.651% less volatile than S&P 500. In comparison iBio has a beta of -3.256, suggesting its less volatile than the S&P 500 by 425.568%.

  • Which is a Better Dividend Stock PTN or IBIO?

    Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PTN or IBIO?

    Palatin Technologies quarterly revenues are $350K, which are larger than iBio quarterly revenues of $200K. Palatin Technologies's net income of -$7.8M is lower than iBio's net income of -$4.4M. Notably, Palatin Technologies's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
    IBIO
    iBio
    -- -- $200K -$4.4M
  • Which has Higher Returns PTN or NBY?

    NovaBay Pharmaceuticals has a net margin of -2357.27% compared to Palatin Technologies's net margin of -49.65%. Palatin Technologies's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About PTN or NBY?

    Palatin Technologies has a consensus price target of $17.00, signalling upside risk potential of 1617%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PTN
    Palatin Technologies
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is PTN or NBY More Risky?

    Palatin Technologies has a beta of 0.873, which suggesting that the stock is 12.651% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.493%.

  • Which is a Better Dividend Stock PTN or NBY?

    Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PTN or NBY?

    Palatin Technologies quarterly revenues are $350K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Palatin Technologies's net income of -$7.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Palatin Technologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns PTN or NNVC?

    Nanoviricides has a net margin of -2357.27% compared to Palatin Technologies's net margin of --. Palatin Technologies's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
    NNVC
    Nanoviricides
    -- -$0.23 --
  • What do Analysts Say About PTN or NNVC?

    Palatin Technologies has a consensus price target of $17.00, signalling upside risk potential of 1617%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 388.72%. Given that Palatin Technologies has higher upside potential than Nanoviricides, analysts believe Palatin Technologies is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    PTN
    Palatin Technologies
    0 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is PTN or NNVC More Risky?

    Palatin Technologies has a beta of 0.873, which suggesting that the stock is 12.651% less volatile than S&P 500. In comparison Nanoviricides has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.901%.

  • Which is a Better Dividend Stock PTN or NNVC?

    Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PTN or NNVC?

    Palatin Technologies quarterly revenues are $350K, which are larger than Nanoviricides quarterly revenues of --. Palatin Technologies's net income of -$7.8M is lower than Nanoviricides's net income of -$3.1M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
    NNVC
    Nanoviricides
    -- -- -- -$3.1M
  • Which has Higher Returns PTN or OGEN?

    Oragenics has a net margin of -2357.27% compared to Palatin Technologies's net margin of --. Palatin Technologies's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About PTN or OGEN?

    Palatin Technologies has a consensus price target of $17.00, signalling upside risk potential of 1617%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 33482.08%. Given that Oragenics has higher upside potential than Palatin Technologies, analysts believe Oragenics is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    PTN
    Palatin Technologies
    0 0 0
    OGEN
    Oragenics
    0 0 0
  • Is PTN or OGEN More Risky?

    Palatin Technologies has a beta of 0.873, which suggesting that the stock is 12.651% less volatile than S&P 500. In comparison Oragenics has a beta of 0.380, suggesting its less volatile than the S&P 500 by 62.042%.

  • Which is a Better Dividend Stock PTN or OGEN?

    Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PTN or OGEN?

    Palatin Technologies quarterly revenues are $350K, which are larger than Oragenics quarterly revenues of --. Palatin Technologies's net income of -$7.8M is lower than Oragenics's net income of -$2.5M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
    OGEN
    Oragenics
    1.05x -- -- -$2.5M
  • Which has Higher Returns PTN or TOVX?

    Theriva Biologics has a net margin of -2357.27% compared to Palatin Technologies's net margin of --. Palatin Technologies's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
    TOVX
    Theriva Biologics
    -- -$6.81 --
  • What do Analysts Say About PTN or TOVX?

    Palatin Technologies has a consensus price target of $17.00, signalling upside risk potential of 1617%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6228.67%. Given that Theriva Biologics has higher upside potential than Palatin Technologies, analysts believe Theriva Biologics is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    PTN
    Palatin Technologies
    0 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is PTN or TOVX More Risky?

    Palatin Technologies has a beta of 0.873, which suggesting that the stock is 12.651% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.217, suggesting its more volatile than the S&P 500 by 21.656%.

  • Which is a Better Dividend Stock PTN or TOVX?

    Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PTN or TOVX?

    Palatin Technologies quarterly revenues are $350K, which are larger than Theriva Biologics quarterly revenues of --. Palatin Technologies's net income of -$7.8M is lower than Theriva Biologics's net income of -$7.7M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock